Table 2.
Prognostic value of MYPT1/CD31 combined expression for the biochemical recurrence-free, metastasis-free and overall survival in univariate and multivariate analysis using Cox Regression models.
| Features | BCR-free survival | Met-free survival | Overall survival | ||||||
|---|---|---|---|---|---|---|---|---|---|
| HR | 95% CI | P | HR | 95% CI | P | HR | 95% CI | P | |
|
Univariate analysis |
|||||||||
| MYPT1 /CD31 | 0.281 | 0.150-0.525 | <0.001 | 0.105 | 0.014-0.814 | 0.031 | 2.343 | 1.081-5.078 | 0.031 |
| CD31 | 1.834 | 1.173-2.867 | 0.008 | 3.663 | 1.215-11.039 | 0.021 | 0.975 | 0.465-2.045 | 0.946 |
| AJCC patho- logical stage |
1.552 | 0.861-2.795 | 0.144 | 1.796 | 0.482-6.689 | 0.383 | 1.351 | 0.624-2.927 | 0.446 |
| Gleason score | 6.031 | 2.548-14.272 | <0.001 | 4.783 | 0.598-28.251 | 0.140 | 3.023 | 1.149-7.953 | 0.025 |
| PSA level | 3.764 | 0.910-15.570 | 0.067 | 1.176 | 0.147-9.426 | 0.878 | 1.118 | 0.333-3.748 | 0.857 |
| Age | 1.426 | 0.777-2.620 | 0.252 | 0.747 | 0.155-3.599 | 0.716 | 1.990 | 0.941-4.212 | 0.072 |
|
Multivariate analysis |
|||||||||
| MYPT1 /CD31 | 0.366 | 0.183-0.734 | 0.005 | 0.139 | 0.017-1.113 | 0.043 | 1.551 | 0.506-2.910 | 0.353 |
| CD31 | 1.271 | 0.755-2.139 | 0.367 | 3.413 | 0.937-12.430 | 0.063 | 1.214 | 0.615-3.914 | 0.664 |
| AJCC patho- logical stage |
1.042 | 0.558-1.945 | 0.897 | 1.158 | 0.342-3.923 | 0.814 | 0.887 | 0.358-2.197 | 0.796 |
| Gleason score | 3.360 | 1.740-6.491 | <0.001 | 2.727 | 0.759-9.797 | 0.124 | 1.646 | 0.535-5.065 | 0.385 |
| PSA level | 1.678 | 0.650-4.329 | 0.284 | 0.402 | 0.112-1.440 | 0.162 | 0.631 | 0.168-2.372 | 0.496 |
| Age | 1.244 | 0.678-2.284 | 0.481 | 0.981 | 0.245-3.924 | 0.979 | 2.157 | 0.918-5.068 | 0.078 |